Impaired energetics in heart failure: A new therapeutic target

Jane Ormerod, Houman Ashrafian, Michael Frenneaux

Research output: Contribution to journalLiterature reviewpeer-review

12 Citations (Scopus)


Heart failure is a syndrome of huge and growing importance worldwide. It is widely accepted that the energy status of the myocardium in heart failure is impaired, irrespective of etiology. Agents which modify cardiac substrate utilisation have the potential to ameliorate this energy deficiency by increasing cardiac mechanical efficiency. This may represent a new therapeutic paradigm in heart failure. In this review we discuss existing and new agents that alter cardiac substrate use and summarise the data on clinical efficacy. (C) 2008 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)264-274
Number of pages11
JournalPharmacology & Therapeutics
Issue number3
Early online date17 Jun 2008
Publication statusPublished - Sept 2008


  • myocardial energetics
  • heart failure
  • metabolic agents
  • fatty-acid oxidation
  • glucose-insulin-potassium
  • left-ventricular function
  • activated protein-kinase
  • randomized controlled-trial
  • percutaneous coronary intervention
  • ischemic dilated cardiomyopathy
  • elevation myocardial-infarction
  • coenzyme-A thiolase
  • mitochondrial biogenesis


Dive into the research topics of 'Impaired energetics in heart failure: A new therapeutic target'. Together they form a unique fingerprint.

Cite this